Genus PLC
ISIN: GB0002074580 | Ticker: GNS | LEI: 54930022EOITNKSIGH56
Country: United Kingdom
Genus PLC is a leading global animal genetics company that specializes in developing high-quality breeding livestock for the agricultural industry. With more than 50 years of experience, Genus has a proven track record of delivering innovative and sustainable solutions to help farmers improve their productivity and profitability.
Genus leverages advanced genetic technology and state-of-the-art research facilities to develop superior breeding livestock that is adaptable to different farming systems and environments. The company's portfolio includes a wide range of products such as dairy and beef cattle, pigs, and sheep that are designed to meet the unique needs of farmers across the world.
1933
Served areaWorldwide
Headcount3,500
HeadquartersMatrix, Basing View, RG21 4DZ Basingstoke – United Kingdom
| Line item in (gbp) | 01.07.2021 | 01.07.2022 | 01.07.2023 |
|---|---|---|---|
| Assets | N/A | 1,017,900,000.00 | 1,007,500,000.00 |
| Noncurrent Assets | N/A | 760,400,000.00 | 748,500,000.00 |
| Property Plant And Equipment | N/A | 171,400,000.00 | 164,400,000.00 |
| Goodwill | N/A | 111,000,000.00 | 107,800,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 72,000,000.00 | 66,200,000.00 |
| Investment Accounted For Using Equity Method | N/A | 41,200,000.00 | 53,500,000.00 |
| Noncurrent Biological Assets | N/A | 333,700,000.00 | 318,200,000.00 |
| Other Noncurrent Receivables | N/A | 8,600,000.00 | 8,200,000.00 |
| Deferred Tax Assets | N/A | 10,100,000.00 | 16,500,000.00 |
| Noncurrent Derivative Financial Assets | N/A | 2,200,000.00 | 4,900,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 10,200,000.00 | 8,800,000.00 |
| Current Assets | N/A | 257,500,000.00 | 259,000,000.00 |
| Inventories | N/A | 50,900,000.00 | 61,300,000.00 |
| Trade And Other Current Receivables | N/A | 129,500,000.00 | 132,100,000.00 |
| Current Biological Assets | N/A | 33,100,000.00 | 23,800,000.00 |
| Cash and cash equivalents | 46,000,000.00 | 38,800,000.00 | 36,300,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 200,000.00 | 0.00 |
| Current Derivative Financial Assets | N/A | 1,000,000.00 | 1,500,000.00 |
| Equity | -1,500,000.00 | 572,100,000.00 | 567,200,000.00 |
| Issued Capital | N/A | 6,600,000.00 | 6,600,000.00 |
| Retained Earnings | N/A | 340,600,000.00 | 360,600,000.00 |
| Share Premium | N/A | 179,100,000.00 | 179,100,000.00 |
| Treasury Shares | N/A | 100,000.00 | 100,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 578,500,000.00 | 574,900,000.00 |
| Noncontrolling Interests | N/A | -6,400,000.00 | -7,700,000.00 |
| Liabilities | N/A | 445,800,000.00 | 440,300,000.00 |
| Noncurrent Liabilities | N/A | 294,500,000.00 | 293,100,000.00 |
| Noncurrent Provisions | N/A | 12,000,000.00 | 10,300,000.00 |
| Noncurrent Payables | N/A | 200,000.00 | 0.00 |
| Deferred Tax Liabilities | N/A | 60,300,000.00 | 51,200,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 8,300,000.00 | 6,900,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 6,400,000.00 | 6,200,000.00 |
| Longterm Borrowings | N/A | 182,100,000.00 | 196,000,000.00 |
| Current Liabilities | N/A | 151,300,000.00 | 147,200,000.00 |
| Current Provisions | N/A | 1,900,000.00 | 1,800,000.00 |
| Trade And Other Current Payables | N/A | 124,700,000.00 | 122,000,000.00 |
| Current Derivative Financial Liabilities | N/A | 1,800,000.00 | 1,800,000.00 |
| Line item in (gbp) | 01.07.2021/ 01.07.2022 |
01.07.2022/ 01.07.2023 |
|---|---|---|
| Revenue | 593,400,000.00 | 689,700,000.00 |
| Expense From Sharebased Payment Transactions With Employees | 3,700,000.00 | 6,000,000.00 |
| Amortisation Expense | 8,300,000.00 | 7,700,000.00 |
| Other Gains Losses | 0.00 | 2,700,000.00 |
| Profit Loss From Operating Activities | 49,400,000.00 | 40,500,000.00 |
| Finance Income | 400,000.00 | 1,100,000.00 |
| Finance Costs | 6,600,000.00 | 15,400,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 5,200,000.00 | 10,500,000.00 |
| Profit Loss Before Tax | 48,400,000.00 | 39,400,000.00 |
| Income Tax Expense Continuing Operations | 11,700,000.00 | 7,600,000.00 |
| Profit (loss) | 36,700,000.00 | 31,800,000.00 |
| Profit Loss Attributable To Owners Of Parent | 40,900,000.00 | 33,300,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -4,200,000.00 | -1,500,000.00 |
| Line item in (gbp) | 01.07.2021 | 01.07.2022 | 01.07.2023 |
|---|---|---|---|
| Profit (loss) | N/A | 36,700,000.00 | 31,800,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -67,200,000.00 | -30,900,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 3,400,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 1,000,000.00 | 400,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 2,400,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 42,100,000.00 | 25,900,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 8,800,000.00 | 9,300,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 34,300,000.00 | 50,400,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 138,700,000.00 | 126,800,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 83,900,000.00 | 111,700,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 11,300,000.00 | 11,100,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 20,900,000.00 | 21,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 21,900,000.00 | -18,200,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -11,000,000.00 | 1,300,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 3,800,000.00 | -3,800,000.00 |
| Cash and cash equivalents | 46,000,000.00 | 38,800,000.00 | 36,300,000.00 |
Please note that some sums might not add up.
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| GLG Partners LP | 0.69% | 11.07.23 |
| JPMorgan Asset Management (UK) Ltd | 0.54% | 29.02.24 |
| GLG Partners LP | 0.71% | 31.08.23 |
| GLG Partners LP | 0.52% | 29.11.23 |
| GLG Partners LP | 0.69% | 07.09.23 |
| Total | 3.15% |
GB0002074580
LEI54930022EOITNKSIGH56
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE 250
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.